ALK and non-small cell lung carcinoma: In line with these findings, we for the first time systematically showed that METF exerted a dose-dependent growth inhibitory effects on 5 NSCLC cell lines (HCC4006, NCI-H1975, HCC95, NCI-H2122, NCI-H3122) carrying various EGFR, KRAS, EML4/ALK and LKB1 genotypes irrespective of Gefitinib sensitivity.